Drug Profile
Research programme: CCR5/CXCR4 antagonists - Millennium/Pfizer
Latest Information Update: 20 Nov 2003
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; Pfizer
- Class Small molecules
- Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections; Rheumatoid arthritis
Most Recent Events
- 20 Nov 2003 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 20 Nov 2003 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 30 May 2002 Pfizer has licensed patent rights to CCR5 from Euroscreen